Hot Features
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader curre... Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.25 | -5.05050505051 | 4.95 | 5.3 | 4.71 | 54206 | 5.0711965 | CS |
| 4 | -0.83 | -15.0090415913 | 5.53 | 5.89 | 4.66 | 45200 | 5.13379307 | CS |
| 12 | -0.03 | -0.634249471459 | 4.73 | 6.28 | 4.59 | 60929 | 5.29548721 | CS |
| 26 | 3.991 | 562.905500705 | 0.709 | 7.5612 | 0.5321 | 625371 | 1.13186134 | CS |
| 52 | 3.84 | 446.511627907 | 0.86 | 7.5612 | 0.5321 | 803458 | 0.98548141 | CS |
| 156 | 3.771 | 405.920344456 | 0.929 | 7.5612 | 0.5321 | 825561 | 1.14514714 | CS |
| 260 | 0.76 | 19.2893401015 | 3.94 | 9.8 | 0.5 | 2031641 | 3.45794467 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.